generic glp-1 receptor agonists FDA Approves First Weight Loss Drug Liraglutide Injection Marks Debut as

We filed for FDA approval of Wegovy pill in February 2025, and our submission was accepted in May 2025

doi: 10.1210/endo.135.5.7956929

Incidence of end-stage renal disease following bariatric surgery in the Swedish Obese Subjects Study

The SURMOUNT-4 trial assessed the weight maintenance with tirzepatide and had also two periods: a 36-week open-label lead-in period during which all participants took tirzepatide, followed by a 52-week double-blind treatment period during which participants were randomised to either continue on tirzepatide or switch to placebo

Weight loss on GLP-1 drugs depends on the medication type and dosage

also reported a low risk of hypoglycemia, with events occurring in similar proportions of patients with obesity but without diabetes who were treated with liraglutide 3.0 mg (1.3%) compared with placebo (1.0%) [37]